The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
In late March and early April 2026, Incyte reported positive 54-week Phase 3 data for its JAK1 inhibitor povorcitinib in hidradenitis suppurativa and Adagene announced entering a clinical ...
Hosted on MSN
Jefferies downgrades Incyte (INCY)
Fintel reports that on March 16, 2026, Jefferies downgraded their outlook for Incyte (NasdaqGS:INCY) from Buy to Hold. Analyst Price Forecast Suggests 17.55% Upside As of February 25, 2026, the ...
Check out some of the companies making the biggest moves midday: Amentum Holdings — The defense contractor tumbled about 12% after fiscal first-quarter revenue and adjusted EBITDA missed Wall Street ...
Incyte (INCY) on Monday posted a Phase 3 trial win for tafasitamab, an antibody therapy it has developed with Xencor (XNCR), setting up a potential label expansion for the drug as a first-line option ...
We recently published Wall Street Can’t Keep up With These 10 Crushing Stocks; 6 at Fresh Record Highs. Incyte Corp. (NASDAQ:INCY) is one of the best-performing on Monday. Incyte extended its winning ...
Incyte Corporation (NASDAQ:INCY) ranks among the most undervalued NASDAQ stocks to buy now. Citizens JMP reaffirmed its Market Perform rating on Incyte Corporation (NASDAQ:INCY) on September 18 after ...
Check out the companies making headlines before the bell: Norwegian Cruise Line — Shares of the cruise operator rose 4% on the back of an upgrade from JPMorgan to overweight from neutral. The firm is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results